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Background: West Nile virus (WNV) causes a spectrum of human disease ranging from
a febrile illness (WNV fever) to severe neuroinvasive disease (meningitis, encephalitis,
acute flaccid paralysis). Since WNV gained entry into North America in 1999,
clinicians caring for WNV survivors have observed persistent neurological symptoms
occurring long-after the production of neutralizing antibodies and clearance of the
virus. Accordingly, alternative pathogeneses other than direct viral invasion have been
hypothesized to explain these post-infectious symptoms. The dominant hypothesis is
that antiviral inflammatory responses triggered initially to clear WNV may persist to
promote a post-infectious proinflammatory state.
Methods: In 4 serologically-confirmed WNV patients with persistent post-infectious
symptoms (3WNV fever, 1 neuroinvasive disease), we ordered a comprehensive cytokine
panel at weeks 8, 10, 12, and 36 months post-onset of illness, respectively, to better
understand the pathophysiology of the protracted symptoms.
Results: All patients had abnormally elevated tumor necrosis factor alpha (TNF-α), a
major molecule triggering antiviral cytokines and chronic inflammation in many human
autoimmune diseases, but heretofore not reported to be upregulated in human WNV
infection. Three patients also had elevations of other proinflammatory proteins. Major
symptoms included fatigue, arthralgias, myalgias, generalized or multifocal pain or
weakness, imbalance, headaches, cognitive problems, and symptoms of dysautonomia.
Conclusion: The findings provide support for an extended post-infectious
proinflammatory state that may contribute to chronic inflammation and long-term
morbidity in some WNV survivors and further suggest that TNF-α may play a
pathogenic role in initiating this inflammatory environment. Clinical trials may bewarranted
to determine if TNF-α inhibitors or other immunosuppressive agents can improve
patient outcomes.
Keywords: West Nile virus, fever, immunity, neuroinvasive disease, cytokines, tumor necrosis factor,
neuroinflammation
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INTRODUCTION
West Nile virus (WNV) is a neurotropic flavivirus that causes a
spectrum of human disease ranging from a febrile illness (WNV
fever) to severe neuroinvasive disease classified as meningitis,
encephalitis, or acute flaccid paralysis (poliomyelitis variant)
(1). In neuroinvasive disease, neuronal loss attributed to direct
viral invasion of neurons is the presumed pathological substrate
for the high morbidity and mortality. However, since WNV
gained entry into North America in the New York City outbreak
of 1999 (2), clinicians caring for WNV survivors, including
those with WNV fever, have observed persistent symptoms
and delayed neurological deficits long after the production of
neutralizing antibodies and clearance of the virus. In fact, from
1999 to late 2002, a total of 2,671 cases of human illness were
reported to the Centers for Disease Control and Prevention
(CDC) and all attempts to recover WNV from these patients
failed (3), suggesting that once neutralizing antibodies are formed
the virus is rapidly cleared. To date, it is commonly accepted
that infectious WNV cannot be isolated from humans with a
normal immune system following the production of neutralizing
antibodies (4, 5). There is also no convincing evidence that
WNV can establish a persistent infection or remain dormant
in the human body after the primary infection. Accordingly,
alternative pathogeneses other than direct viral invasion have
been hypothesized to explain the protracted or delayed post-
infectious symptoms, which occur in up to 50% of convalescent
patients (6). On a molecular level, acute WNV infection induces
a significant upregulation of various proinflammatory proteins,
including astroglial protein S100B and the receptor for advanced
glycation end products (RAGE) (7), high-mobility group box-1
(HMGB1) (8), and osteopontin (OPN) (9), which initiate and
maintain an inflammatory cascade that increases production of
pro-inflammatory cytokines, interleukins (ILs), and chemokines
(10–12) as part of the initial antiviral immune response. Previous
studies in mice and cell cultures have demonstrated essential
protective roles for these proinflammatory proteins against acute
WNV infection (13, 14). However, these antiviral molecules have
also been reported to persist for months following the acute
illness, leading to a post-infectious proinflammatory state that
may contribute to long-term neuroinflammation and cytotoxicity
in some WNV survivors (15, 16).
In 4 patients with persistent post-WNV symptoms, we
ordered a comprehensive cytokine panel to better understand
the pathophysiology of these protracted symptoms. Three were
classified as WNV fever and one as neuroinvasive disease by
the Mississippi State Health Department according to clinical
features based on criteria established by the Centers for Disease
Control and Prevention (CDC) (1). In all, the cytokine panel
was collected long after the virus had presumably been cleared
by the immune system (at weeks 8, 10, 12, and 36 months
post-onset of illness). All 4 patients had elevated levels of TNF-
α. Heretofore, upregulation of TNF-α has not been reported
in human WNV clinical infection despite general recognition
that TNF-α is a major molecule triggering antiviral cytokines
in neuroinflammation and many other human autoimmune
diseases (10, 13, 17). Three patients also had elevations of other
proinflammatory cytokines. These findings provide additional
support for an extended post-infectious pro-inflammatory state
that may contribute to chronic neuroinflammation and long-
term morbidity in some WNV survivors and further suggest
that TNF-α may play a pathogenic role in initiating this
proinflammatory environment.
METHODS
This retrospective case series was approved by the Institutional
Review Board for Human Research at Methodist Rehabilitation
Center. Patients also gave approval for their case reports to be
published in medical journals. All 4 patients lived in Mississippi
and developed an acute febrile illness during the summer with
onset of symptoms in August 2017 (2 cases), August 2018 (1
case) and September 2014 (one case). All had a positive WNV
IgM antibody in the context of the febrile illness and developed
persistent severe post-infectious symptoms. In all, we ordered
a commercially available comprehensive cytokine panel (Mayo
Clinic test I.D. FCYTP; ARUP Laboratories I.D. 0051394) to
better understand the immune physiology of the protracted
symptoms. Quantitativemultiplex bead assay was used to identify
the cytokines. Patients’ sera were collected at weeks 8, 10, 12,
and 36 months post-onset of illness, respectively. The cytokine
panel included TNF-α, interferon gamma (IFN-γ), IL-2, IL-
2 receptor (CD 25) soluble, IL-12, IL-4, IL-5, IL-10, IL-13,
IL-17, IL-1-beta, IL-6, IL-8, and protein S100B. Cytokines on
this panel are key regulators of innate and adaptive immune
responses. IL-2, IL-6, IL-12, and IFN-γ have also been reported
to be increased in WNV patients with prolonged post-infectious
symptoms (16). IL-17 is upregulated by WNV infection in
humans and also plays a vital role in the pathogenesis of other
human autoimmune diseases (12). In addition, WNV infection
significantly upregulates S100B, an important proinflammatory
glial protein that is increased in human serum and cerebrospinal
fluid (CSF) post-WNV infection (7). S100B binds to the receptor
for advanced glycation end products (RAGE), which promotes
and amplifies autoimmune and chronic inflammatory diseases
(7, 8). WNV activated macrophages also produce a large number
of antiviral cytokines found on this panel, including TNF-α, INFs,
IL-6, IL-8, and IL-1-beta (18). Importantly, all patients attributed
their lingering symptoms to WNV infection.
Case Series
Patient 1
A 49-year-old law enforcement officer was in relatively good
health prior to WNV infection with treated depression and
hypertension and a history of isolated surgery for a rectal abscess.
He developed high fever (104◦C), chills (“trembling like a wet
noodle”), confusion, weakness in both lower limbs, and urinary
retention. He was initially diagnosed as “serotonin syndrome”
because he was on fluoxetine, but the medical team revised the
diagnosis to recurrent rectal abscess with sepsis (“because he
looked so toxic”) and requested surgical intervention, despite a
normal white cell count. Under general anesthesia, the surgeon
found no evidence of recurrent rectal abscess and informed
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the patient that “the abscess is not what made you sick,
there’s something else going on.” Upon tracheal extubation the
patient had a respiratory arrest requiring mechanical ventilation
for 3 days. Persistent symptoms over the ensuing 8 weeks
included disabling fatigue (“still feeling awful”), imbalance,
generalized and focal weakness, increased anxiety, restlessness,
tremors, generalized pain (“whole body”), and additional pain
in joints (“achy painful joints everywhere”). On neurological
examination there was mild weakness in both lower limbs
(Medical Research Council, MRC, scale 4/5) and left upper limb
(4/5) with myoclonic-like jerks, bilateral hand tremors, slight
dysmetria on finger-nose testing and slight gait ataxia with several
near-falls during tandem gait. He was diagnosed with WNV
neuroinvasive disease. A cytokine panel performed 8 weeks
after onset of symptoms showed elevated TNF-α with equivocal
S100B (Table S1). Normal laboratory tests included complete
blood count (CBC), C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), antinuclear antibody (ANA), complete
metabolic panel (CMP), and paraneoplastic panel (the latter
panel was ordered because of a 36-lb weight loss and a strong
family history of cancer). Repeat cytokine panel 21 months after
onset of symptoms was normal with TNF-α <5 pg/mL and S100B
(76 ng/L).
Patient 2
A 53-year-old woman with a history of asymptomatic alpha 1-
antitrypsin deficiency and Hashimoto’s thyroiditis developed an
acute febrile illness with maculopapular rash and neck stiffness
diagnosed as WNV fever. This was followed by persistent
symptoms for 10 weeks (“still feeling awful”), including extreme
fatigue, insomnia, imbalance, dizziness, persistent low grade
fever, difficulty concentrating, daily headaches, paresthesias in
limbs, muscle and joint pains, and anxiety and depression (“my
life as a teacher has turned upside down”). Cytokine panel,
performed 10 weeks after onset of symptoms showed elevated
TNF-α and interleukin (IL)-2 receptor (CD 25) soluble protein
with equivocal S100B (Table S1). The ESR was slightly elevated
at 28 mm/h. Neurological examination was unremarkable. The
patient was placed on short-term disability for 4 months, but
she was “unable to function as a school teacher” because of
the extreme fatigue and difficulty concentrating. Repeat cytokine
panel 20 months after onset of symptoms showed a normal TNF-
α (14 pg/mL) but increased soluble IL-2 receptor (CD 25) to 1571
pg/mL, a cytokine that reflects ongoing immune activation and
inflammation (19). Disability was extended for an additional 3
months (total 7 months) before she was able to return to work.
Patient 3
A 34-year-old woman in relatively good health except for
occasional migraine headaches and chronic nonspecific “colitis”
developed an acute febrile illness with maculopapular rash in
face and limbs diagnosed as WNV fever. Acute symptoms
persisted for 12 weeks, including severe fatigue, weight loss,
hand tremors (“I can barely write my name”), difficulty with
“hand/eye coordination,” severe muscle aches in calves and
thigh muscles, joint pains “all over,” and right lower limb
muscle “jerking and jumping.” Inspection of several videos
provided by the patient confirmed involuntary repetitive right
quadriceps myoclonic-like jerks involving the entire length
of the muscle. Dysautonomic symptoms were prominent and
included anxiety, a feeling of total body hyperexcitability “with
my legs shaking when I walk,” palpitations, irregular heart
rate and postural lightheadedness and orthostatic tachycardia
attributed to dehydration by her physicians. She also developed
severe diarrhea in the month following the acute WNV illness
with negative stool cultures that was attributed to a “flare-
up” of her colitis. Prior to WNV, the colitis had been well
controlled with only mesalamine (5-aminosalicylic acid) for the
prior 2 years. She was treated with Flagyl (metronidazole) for
2 weeks for possible infectious colitis and repeat cultures a
month later identified Clostridium difficile. A cytokine panel,
performed 12 weeks after onset of symptoms, showed elevated
TNF-α and IFN-γ (Table S1). Initial neurological examination
showed focal weakness (4/5) in right anatomical leg and thigh
muscles associated with relative hyporeflexia. Electrodiagnostic
studies showed decreased cumulative compound muscle action
potential (CMAP) amplitudes from right peroneal, tibial and
femoral nerves (26.9mV) compared with 37.7mV on the left.
In contrast, cumulative sensory nerve action potential (SNAP)
amplitudes from sural, superficial peroneal and saphenous nerves
were symmetrical (66 µV on the right and 60 µV on the
left). Needle EMG showed fibrillation potentials in multiple
muscles of the right lower limb including tibialis anterior,
medial and lateral gastrocnemius, quadriceps, and iliopsoas. The
findings confirmedWNVneuroinvasive disease, despite the prior
classification as WNV fever, with limited acute flaccid paralysis
(poliomyelitis variant) involving the right lower limb. Laboratory
tests to exclude underlying autoimmune disorders were normal,
including CBC, CRP, ESR, CMP, ANA, rheumatoid factor (RF),
and total creatine kinase (CK). Repeat cytokine panel performed
5 months after onset of symptoms was normal. At that time,
many of her symptoms had improved although she was “not
back to normal.” At 9 months follow-up, she still had moderate
fatigue, decreased stamina, persistent soreness in legs “not related
to the amount of physical activity”, and paresthesias in both
legs, “like the ends of fibers are just ‘pinging’ continuously.”
Dysautonomia symptoms also improved, although she had
residual focal areas of hyperhidrosis and persistent “trouble
adjusting my internal temperature.”
Patient 4
A 38-year-old woman developed an acute illness diagnosed as
WNV fever followed by persistent symptoms for 36 months,
including severe post-exertion fatigue, generalized weakness,
imbalance, muscle aches (myalgias), joint pain (arthralgias),
low back pain, generalized dysesthesias (“my whole body feels
inflamed”) superimposed on subjective low-grade fever, facial
flushing, worsening migraines, poor sleep, and dysautonomia
symptoms (bladder incontinence, constipation, increased anxiety
attributed to a persistent “stressed out feeling” and palpitations).
Cognitive issues included difficulty concentrating, memory
lapses and increased irritability. She was a former college
athlete and a physical therapist in good health prior to
WNV with only occasional migraine headaches. The cytokine
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panel, performed 36 months after onset of symptoms, showed
elevated TNF-α, IFN-γ, and IL-13, with equivocal S100B
(Table S1). Pertinent normal laboratory tests included CBC,
CRP, ESR, ANA, extractable nuclear antigen (ENA), RF,
CK, human immunodeficiency virus (HIV), syphilis serology,
CMP, Lyme serology, monoclonal protein study, thyroid
functions, and paraneoplastic panel. Neurological examination,
including mini-mental status assessment, was unremarkable.
Following WNV infection, the patient failed treatment by
doctors in multiple specialties (internal medicine, cardiology,
gastroenterology, rheumatology, and neurology) directed at
symptoms arising from organ systems in their respective fields.
In all subjects, we ordered a trial of TNF-α-blocking
agents after discovering that WNV post-infectious symptoms
were associated with pathological levels of TNF-α. However,
immunotherapy was denied by the insurance companies because
this treatment did not meet their medical necessity guidelines
and peer-reviewed medical literature did not support the use
of these agents for treatment of TNF-α symptoms related to a
WNV diagnosis. Demographic, laboratory and chief persistent
symptoms of the 4 cases are shown in Table S1. Fatigue and
pain were the most common persistent symptoms, shared by all
4 subjects. The pain primarily presented as arthralgias (n = 4),
myalgias (n= 3), or generalized or multifocal pain (n= 2). Three
of 4 also complained of generalized or focal weakness, imbalance,
and anxiety. Two had symptoms of persistent low-grade fever,
headaches, difficulty concentrating, tremors, sleep disruption,
and symptoms of dysautonomia (palpitations, irregular heart
rate, postural intolerance, orthostatic tachycardia, diarrhea,
hyperhidrosis, and changes in bowel or bladder function).
DISCUSSION
We present four WNV patients with persistent post-infectious
symptoms associated with elevated levels of TNF-α and other
proinflammatory cytokines that promote chronic inflammation.
The present case series extends previous reports of elevated
cytokines in WNV survivors (16, 18, 20) and includes three
original observations. First, the clinical data provide evidence
thatWNV infection in humans induces a significant upregulation
of TNF-α. This is not surprising since previous studies in mice
and cell cultures have demonstrated essential protective roles
for TNF-α and other proinflammatory cytokines against acute
WNV infection (10, 12–14) Moreover, high TNF-α levels have
been reported in other flavivirus human infections, including
dengue (21, 22), Zika virus (23, 24), and Japanese encephalitis
virus (JEV) (25). Children infected with dengue virus showed
significantly higher serum levels of TNF-α, with the highest
levels in those with severe dengue disease (21), formerly “dengue
shock syndrome” and “dengue hemorrhagic fever.” In fact, the
potentially critical causative role of TNF-α and the associated
“cytokine storm” in severe dengue disease and other viral diseases
has long been recognized (26). In fatal cases of Zika fetal
syndrome, a significantly increased expression of TNF-α, IFN-
γ, and other proinflammatory cytokines has been found in the
meninges, perivascular region, and parenchyma of microcephalic
brains (23, 24). Japanese encephalitis virus (JEV) infection
also significantly elevates expression of TNF-α and other pro-
inflammatory cytokines in animals and cell cultures, leading to
neuroinflammation and neuronal death (25). Hence, it is not
surprising that we now add TNF-α to the list of proinflammatory
molecules that are upregulated in humans following WNV
infection. Second, the observations suggest that elevated levels
of TNF-α and other antiviral cytokines may persist long after
the virus has been cleared by effective innate and adaptive
immune responses, even in non-neuroinvasive disease cases
classified as WNV fever. Indeed, infectious WNV cannot be
isolated from humans with a normal immune system following
the production of WNV-specific IgM antibodies (3–5), which are
usually detectable 3 to 8 days after onset of clinical illness (1). In
our case series, high TNF-α values were detected at weeks 8, 10,
12, and 36 months post-onset of illness. Repeat cytokine panels
at months 5, 20, and 21 after onset of symptoms showed normal
TNF-α values, suggesting that TNF-αmay play amore prominent
role in initiating rather than maintaining the proinflammatory
environment. In fact, in onemajor study, 44 of 140WNVpatients
(31%) that reported prolonged (> 6 months) post-infectious
symptoms, with an average symptom duration of 5 years, had
significantly elevated pro-inflammatory proteins that included
IL-2, IL-6, IL-12p70, granulocyte macrophage colony stimulating
factor, IFN-γ, and IFN-γ-inducing protein 10, but not TNF-
α (16). Moreover, in case 2, soluble IL-2 receptor (CD 25), an
established inflammatory marker that reflects ongoing immune
activation and inflammation in multiple human autoimmune
diseases (19), increased from 1220 to 1571 (normal<1033
pg/mL) over the ensuing 17 months despite normalization
of TNF-α. These examples are in agreement with TNF-α
being most active in orchestrating the innate immune response
that initiates an inflammatory cascade (13, 17). However, in
case 4, the initial cytokine panel performed 36 months after
onset of illness showed elevated TNF-α, IL-13, IFN-γ, and
equivocal S100B values, suggesting that in some cases TNF-α
may remain elevated for years post-infection. Third, the clinical
evidence supports the contention that TNF-α signaling may
contribute to the persistent symptoms that have plagued WNV
survivors since WNV gained entry into North America in 1999.
Indeed, we ordered the comprehensive cytokine panel to better
understand the pathophysiology of the protracted symptoms
and TNF-α was the only cytokine elevated in all 4 subjects.
In case 3, a “flare-up” of colitis may have contributed to the
elevated TNF-α and IFN-γ. However, the colitis was stable until
WNV infection and the persistent symptoms that brought this
patient and others to medical attention were typical of WNV
infection rather than coexisting disorders. Importantly, the post-
infectious WNV environment has been reported to promote
or amplify various diseases that have a presumed autoimmune
pathogenesis, including Guillain-Barre syndrome, (27) other
demyelinating neuropathies (28), de novomyasthenia gravis (29),
transformation of stable ocular myasthenia gravis to myasthenic
crisis (30), and stiff-person syndrome (31).
TNF-α is widely recognized as a proinflammatory molecule
that serves as an important component of neuroinflammation
and systemic inflammation in many autoimmune diseases (11,
13, 17). TNF-α and other antiviral proinflammatory cytokines
initially protect against WNV infection in animal models
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(12–14). Treatment of cells with a neutralizing anti-TNF-α
monoclonal antibody initially decreases survival in mice during
the acute WNV infection (11, 15), when antiviral cytokines are
needed to clear the virus. In contrast, administration of the
same anti-TNF-α treatment at a later stage of infection results
in a significant reduction of WNV-mediated neuronal death,
suggesting that persistence of such proinflammatory mediators
may play a major role in the pathogenesis of WNV infection
in the CNS (11, 15). In a longitudinal cross-sectional study to
assess changes in neurological status over time, neurological
examinations were performed 1–3 years and 8–11 years post-
WNV infection in 60 WNV patients (35 encephalitis, 14
meningitis, 11 WNV fever) (32). By the time of the second
assessment, 36% of encephalitis, 33% of meningitis, and 57% of
WNV fever cases had developed new neurological complications.
The authors concluded that long-term neurological deficits may
develop years later, regardless of the severity of the initial WNV
infection (32). The clinical data from this longitudinal study, in
conjunction with several studies showing that proinflammatory
cytokines can be chronically elevated in WNV survivors (16, 18,
20), support the concept of a pathogenic role for persistent virus-
specific immunity. Importantly, the receptors of cytokines are
expressed constitutively throughout the CNS, including neurons,
thereby rendering them sensitive to cytokines even at very low
levels (10). IFN-γ, which was elevated in cases 3 and 4, also
induces proinflammatory chemokines that are important triggers
of inflammation in the brain (10, 33). The early up-regulation of
these chemokines in the CNS coincides with the up-regulation of
TNF-α at the same site in a rodent model of WNV infection (33).
Collectively, the evidence supports the concept that an extended
elevation of TNF-α and other proinflammatory cytokines in
WNV survivors, as in other autoimmune and inflammatory
diseases, plays a causal rather than a coincidental role in the
development of protracted or delayed symptoms.
In all four patients a trial of immunotherapy with TNF-α-
blocking agents was denied by respective insurance companies
due to not meeting medical necessity guidelines and because
peer-reviewed medical literature did not support the use
of these agents as safe or effective for treatment of TNF-
related symptoms with a WNV diagnosis. The denials occurred
despite patients’ developing a plethora of symptoms that are
generally recognized as classic for TNF-α-related pathogenesis in
autoimmune diseases such as rheumatoid arthritis and psoriatic
arthritis, including fatigue, weakness, arthralgias, and generalized
or multifocal pain.
CONCLUSION
These cases provide evidence that WNV-induced TNF-
α signaling, which modulates the expression of multiple
inflammatory mediators, may persist in some WNV survivors
and become detrimental, contributing to a post-infectious
pro-inflammatory state linking chronic neuroinflammation with
WNV disease pathogenesis. In such cases, persistent or delayed
neurological symptoms following the production of WNV
neutralizing antibodies is more likely to reflect secondary injury
from the downstream cascade of excitotoxic events and the
secondary wave of neuroinflammation rather than neuronal loss
per se. Greater awareness is needed that this proinflammatory
state may be potentially treatable with drugs that lessen the
inflammatory microenvironment. At present, no specific therapy
has been approved for human use inWNV infection and patients
and family members are often informed that only supportive care
is available. However, the merging knowledge about the immune-
mediated post-infectious pathogenesis of WNV infection has
direct therapeutic implications. Appropriate clinical trials
seem warranted to determine if TNF-α inhibitors or other
immunosuppressive therapies can control this immunological
cascade to improve patient outcomes.
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